Jonathan W Riess

17PUBLICATIONS
242CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Gene expression (incl. microarray and other genome-wide approaches)Predictive and prognostic markersInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jul 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.

|Jun 03, 2026
Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

|Mar 06, 2026
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study.

Helena A Yu, Kwan Ho Tang, Aleksandra A Markovets

|Jan 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

Sarah Waliany, Alissa J Cooper, Stephen V Liu

|Oct 29, 2025
Diversity of BRAF mutations in non-small cell lung cancer and implications on treatment.

Kevin Lu, John Paul Shen, Fernando J Lopez-Diaz

|Oct 28, 2025
Longitudinal Plasma Lipidomics Reveals Distinct Signatures Following Surgery in Patients with Glioblastoma.

John Paul Aboubechara, Yin Liu, Oliver Fiehn

Pageof 3

Frequent Collaborators

4 joint publications

Sarah B Goldberg

3 joint publications

Adrianus Johannes De Langen

3 joint publications

Zofia Piotrowska

3 joint publications

Byoung Chul Cho